Reasons for differences in dose requirements of recombinant human erythropoietin in haemodialysis patients.
Scigalla
P
P
Department of Clinical Research, Boehringer Mannheim GmbH, FRG.
Messinger
D
D
Wieczorek
L
L
D000328:Adult; D000535:Aluminum / Q000633:toxicity; D000740:Anemia / Q000209:etiology / Q000628:therapy*; D000747:Anemia, Hypochromic / Q000150:complications / Q000628:therapy; D004920:Erythropoiesis / Q000502:physiology; D004921:Erythropoietin / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D006961:Hyperparathyroidism / Q000209:etiology; D007239:Infections / Q000150:complications; D000090463:Iron Deficiencies; D007676:Kidney Failure, Chronic / Q000150:complications / Q000628:therapy; D008875:Middle Aged; D009780:Occult Blood; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000627:therapeutic use; D006435:Renal Dialysis / Q000009:adverse effects*
D011994:Recombinant Proteins; D004921:Erythropoietin; D000535:Aluminum